



Testosterone (TESTO) Assay Reagent Kit (CMIA)

Package Insert

INTENDED USE

The Testosterone Assay Reagent Kit (CMIA) is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of testosterone in human serum or plasma.

PACKING SIZE

24 Device/Kit, 30 Device/Kit, 48 Device/Kit, 60 Device/Kit

SUMMARY

Measurements of testosterone are used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, delayed or precocious puberty, impotence in males and in female's hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries and adrenogenital syndromes.

Testosterone is synthesized almost exclusively by the Leydig cells or the testes and promotes the development of the secondary sex characteristics in men and serves to maintain the function of the prostate and seminal vesicles. In women, small quantities are formed in the ovaries. In physiological concentrations, androgens have no specific effects in women. Increased production of testosterone in women can cause virilization (depending on the increase).

PRINCIPLE OF TEST

The testosterone assay is a competitive binding immunoassay for the quantitative measurement of testosterone in human serum, plasma using CMIA technology, with flexible assay protocols.

In the first step, sample and anti-testosterone coated paramagnetic microparticles are combined. The testosterone present in the sample binds to the anti-testosterone coated microparticles. After incubation, testosterone ALP-labeled conjugate is added to create a reaction mixture in the second step. Following wash cycle, substrate is added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units (RLUs). The light production is inversely proportional to the concentration of testosterone in the sample. The amount of analyte in the sample is determined by the analyzer.

REAGENTS

The device is pre-dispensed with buffer needed for single use.

The device is constituted with Buffers described below is the main reagent

Object	Content
Micro-particles Buffer	Anti -testosterone (Sheep, monoclonal) coated Micro-particles in TRIS buffer with protein (bovine) stabilizer. Minimum concentration: 0.1% solid. Preservative: ProClin-300.
Conjugate Buffer	Testosterone- alkaline phosphatase (ALP) labeled conjugate in TRIS buffer with protein (bovine) stabilizer. Preservative: ProClin-300.
Wash Buffer	TRIS buffer with surfactant. Preservative: ProClin-300.
Substrate Buffer	AMPPD, Enhancer, Surfactant, ProClin-300.

Reagent Handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

MATERIALS PROVIDED

- Testosterone Test Device
- Product Insert
- Calibration Solution (optional)
- Control Solution (optional)

MATERIALS REQUIRED BUT NOT PROVIDED

- Analyzer

STORAGE AND STABILITY

- Store at 2-8 °C and avoid light.
 - Do not freeze.
 - Store the reagent kit upright prior to use.
 - Expiration date: up to the stated expiration date.
- Note: The testosterone Reagent Kit must be stored at 2-8 °C in an upright position, and must be used immediately after removal from 2-8 °C storage or the device was opened. Unused reagents should be put back into the kit in time.

SPECIMEN COLLECTION AND STORAGE

Specimen Types

Validated specimen types to be used with this assay:

Specimen Types	Collection Tubes
Human serum	Serum Serum separator tubes
Human plasma	Sodium heparin Lithium heparin Potassium EDTA Sodium EDTA

Other anticoagulants have not been validated for use with this assay.

The instrument does not provide the capability to verify specimen type. It is the responsibility of the operator to verify that the correct specimen types are used in the assay.

Specimen Conditions

- Do not use specimens with the following conditions:
 - heat-inactivated
 - pooled
 - grossly hemolyzed
 - obvious microbial contamination
- For optimal results, serum and plasma specimens should be free of fibrin, red blood cells or other particulate matter.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some specimens especial those from patients receiving anticoagulant or thrombolytic therapy may exhibit increased clotting time. If the specimen is centrifuged before a complete clot forms, the presence of fibrin may cause erroneous results.
- To prevent cross contamination, use of disposable pipettes or pipette tips is recommended.

Preparation for Analysis

- Follow the tube manufacturer's processing instructions for specimen collection tubes.
- Specimens must be mixed THOROUGHLY after thawing, by LOW speed vortex, and centrifuged prior to use to remove red blood cells or particulate matter to ensure consistency in the results.
- Inspect all specimens for bubbles. Remove bubbles with an applicator stick before analysis. Use a new applicator stick for each specimen to prevent cross contamination.

Specimen Storage

Specimen Type	Storage Temperature	Maximum Storage Time
Serum/Plasma	2-8 °C	6 days

- If testing is delayed more than 24 hours, remove serum or plasma from the clot, serum separator or red blood cells.
- If testing is delayed more than 6 days, specimens should be frozen at -10 °C or colder.
- Specimens stored frozen at -10 °C or colder for 3 months showed no performance difference.
- Avoid more than 3 freeze/thaw cycles.

Specimen Shipping

- Before shipping specimens, it is recommended that specimens be removed from the clot, red blood cells, or separator gel.
- When shipping specimens, package and label specimens in compliance with

applicable state, federal and international regulations covering the transport of clinical specimens and infectious substances.

- Specimens may be shipped ambient, at 2-8 °C (wet ice), or frozen (dry ice). Do not exceed the storage time limitations listed above.

INSTRUMENT

The Testosterone Test Device is designed for use on the REALY Analyzer System.

TEST PROCEDURE

Assay Procedure

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer specific assay instructions. Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the digit sequence of numbers. Bring the cooled reagents to approx. 20 °C and place on the reagent disk of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents.

For this test device, the transfer volume of specimens, calibrators or controls into the sample hole is 60 µL. (No less than 60 µL.)

Reagent strips should be left at room temperature between 20 and 25 °C for more than 30 minutes before use and kept away from light.

In order to avoid the magnetic beads adsorbed on the side wall and top due to the upside down and side placement of the reagent strip during transportation, the reagent strip should be mixed by shaking and mixing before use. The reagent strip should be mixed upside down for about 30 seconds, and then the reagent strip should be mixed upward for about 30 seconds. The reagent strip was then gently shaken so that the magnetic beads fell completely to the bottom of the strip.

Calibration

Every Test Device has a barcode label containing specific information for calibration of the particular reagent lot. The pre-defined master curve is adapted to the analyzer using the relevant CalSet.

Calibration frequency: Calibration must be performed before using a new lot of device.

Renewed calibration is recommended as follows:

- After 90 days (when using the same reagent lot on the analyzer);
- As required: e.g. quality control findings outside the defined limits.

Note: Refer to Instruction of Analyzer for the procedure of calibration.

Quality Control

For quality control, please use Control of REALY or Control Universal.

In addition, other suitable control material can be used. Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Specimen Dilution Procedures

Specimens with a testosterone concentration greater than 20 ng/mL will be flagged as ">20 ng/mL" and may be diluted using Manual Dilution Procedure. Use the 1:4 dilution is recommended. The operator must enter the dilution factor in the Patient or Control order screen. The system will use this dilution factor to automatically calculate the concentration of the sample before dilution.

EXPECTED VALUES

Males (7- 18 years)		
Tanner Stage 1		< 0.025 ng/mL
Tanner Stage2		< 0.025-4.32 ng/mL
Tanner Stage3		0.649-7.78 ng/mL
Tanner Stage4		1.80-7.63 ng/mL
Tanner Stage5		1.88-8.82 ng/mL
Females (8- 18 years)		
Tanner Stage 1		< 0.025-0.061 ng/mL
Tanner Stage2		< 0.025-0.104 ng/mL

Tanner Stage3	< 0.025-0.237 ng/mL
Tanner Stage4	< 0.025-0.268 ng/mL
Tanner Stage5	0.046-0.383 ng/mL
Males 20-49 years	2.49-8.36 ng/mL
Males ≥ 50 years	1.93-7.40 ng/mL
Females 20-49 years	0.084-0.481 ng/mL
Females ≥ 50 years	0.029-0.408 ng/mL

Each facility should establish its own reference ranges to assure proper representation of specific populations.

INTERPRETATION OF RESULTS

As interpret the results, the patient's overall clinical situation, including symptoms, medical history and other related data, should be referred to.

LIMITATIONS

- If the testosterone results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.
- For diagnostic purposes, results should be used in conjunction with other data; e.g., symptoms, results of other tests, clinical impressions, etc.
- Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human anti-mouse antibodies (HAMA). Specimens containing HAMA may produce anomalous values when tested with assay kits such as REALY testosterone that employ mouse monoclonal antibodies.
- Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous results may be observed. Additional information may be required for diagnosis.
- Although the REALY testosterone assay is specifically designed to minimize the effects of HAMA and heterophilic antibodies, assay results that are not consistent with other clinical observations may require additional information for diagnosis.

PERFORMANCE CHARACTERISTICS

Linearity
The linearity of Testosterone Reagent Kit was determined by using testosterone calibrator to prepare 6 different specimens, measuring all these specimens follow the test instruction and then do linear fitting, the results show that the linear correlation coefficient (r) was not less than 0.9900.

Precision/Reproducibility
Intra-assay coefficient of variation was evaluated on 3 different levels of control serum. Repeatedly measured 20 times, calculating the coefficient of variation.

Intra-assay Precision			
Control	Mean (ng/mL)	SD (ng/mL)	CV
Level 1	0.094	0.007	7.74%
Level 2	0.696	0.044	6.25%
Level 3	9.521	0.537	5.64%

Inter-assay coefficient of variation was evaluated on three batches of kits. Repeatedly measured 3 different levels of control serum 30 times, calculating the coefficient of variation.

Inter-assay Precision			
Control	Mean (ng/mL)	SD (ng/mL)	CV
Level 1	0.105	0.009	8.52%
Level 2	0.701	0.056	7.95%
Level 3	9.313	0.643	6.91%

Analytical Sensitivity
The analytical sensitivity is defined as the concentration of testosterone equivalent to the mean RLU of 20 replicates of the zero standard minus two standard deviations corresponding to the concentration from the standard curve. The analytical sensitivity is typically less than 0.05ng/mL.

Analytical Specificity
The specificity of the testosterone assay system was assessed by measuring the apparent response of the assay to various potentially cross-reactive analytes.

Compound	Concentration	Cross-reactivity
----------	---------------	------------------

Cortisone	2000 ng/mL	< 0.10%
Dihydrotestosterone	500 ng/mL	< 0.10%
Estradiol (E2)	1000 ng/mL	< 0.10%
Estrone (E1)	1000 ng/mL	< 0.10%
Cortisol	1000 ng/mL	< 0.10%

Interference
The following compounds in both low-level specimen and high-level specimen show no cross-reactivity when tested with the Testosterone Assay Reagent Kit at a concentration below:

Compound	Concentration
Hemoglobin	1000 mg/dL
Bilirubin	50 mg/dL
Triglycerides	1000 mg/dL

Method Comparison
The comparison between the Testosterone Assay Reagent Kit (y) and a commercially available testosterone test kit (x), using clinical samples gave the following correlations (ng/mL):

Linear regression
y=1.0137x-0.0186
r=0.9837
Number of samples measured: 113
The sample concentrations were between about 0.13-14.55 ng/mL.

WARNINGS AND PRECAUTIONS

- For *In Vitro* Diagnostic Use.
- Do not use expired or clearly damaged kits.
- Operating according to the steps described, can make the risk of daily handling patients' samples and blood products into a minimum, however, no matter what the source of the products, handling mode or the previous proof, these potentially infectious substances used shall be in accordance with the unified considerations and Good Laboratory Practice (GLP).
- Proper disinfectant should be used to eliminate pollution.
- Follow local rules and regulations to keep and dispose of these items and containers for these items.
- The ProClin-300 is a potential skin sensitizer. Avoid dumping or splashing this reagent on your skin and clothing. In case of contact with this reagent, wash thoroughly with soap and water.
- Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).
- The reagents should be kept away from light, and unused reagents should be put back into the kit in time and be careful to avoid light.

BIBLIOGRAPHY

1. Rommerts, F.F.G. (2004). Testosterone: an overview of biosynthesis, transport, metabolism and non-genomic actions.In:Nieschlag, E.,Behre,H.M.eds. Testosterone action, deficiency, substitution, 3rd edition. Cambridge, Cambridge University Press,1–38.

2. Wheeler, M.J. (1995). The determination of bio-available testosterone. Ann Clin Biochem 32, 345–357.

3. Kane, J., Middle, J., Cawood, M. (2007). Measurement of serum testosterone in women; what should we do? Ann Clin Biochem 44, 5–15.

4. Rosner, W., Auchus, R.J.,Azzis, R., Sluss, P.M., Raff, H. (2007). Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92, 404–413.

5. Arlt, W. (2006). Androgen therapy in women. Eur J Endocrinol 154, 1–11.

6. Abbott 2nd Generation Testosterone, Kit inserts (IFU).

7. Kicman, A.T. Biochemical and physiological aspects of endogenous androgens. Handb. Exp. Pharmacol. 195, 25-64 (2010).

8. Gomes, R.L., Meredith, W., Snape, C.E., et al. Analysis of conjugated steroid androgens: Deconjugation, derivatisation and associated issues. J. Pharm. Biomed. Anal. 49(5), 1133-1140 (2009).

9. Gower, D.B. Analysis of androgens and their derivatives, Chapter 6, in Steroid Analysis. Makin, H.L.J. and Gower, D.B., editors, 2nd, Springer, New York, 457-558 (2010).

10. Maxey, K.M.,Maddipati, K.R. and Birkmeier, J. Interference in enzyme immunoassays. J. Clin. Immunoassay 15,116-120 (1992).

11. Vermeulen, A., et al., The Apparent Fre e Testosterone Concentration: An Index of

Androgenicity. J. Clin.Endo. Metab. 33:759, 1971.

12. Paulson, J.D., et al., Free Testosterone Concentration in Serum. Elevation is the Hallmark of Hirsutism. Am. J. Obs. Gyneco. 128:851, 1977.

13. Cumming D.C., et al., Non Sex Hormone Bindi ng Globulin Bound Te stosterone as a Marker for Hyperandrogenism. J. Clin. Endo. Metab. 61:873, 1985.

14. Baxendale, P.M., et al., Salivary Te stosterone Relationship to Unbound Plasma Testosterone in Normal and Hypeandrogenic Women. Clin. Endocrinol. 16:595, 1982.

15. Biffignandi, P., et al., Female Hirsutism: Pathophysiological Considerations and Therapeutics Implications. Endocrinol Rev. 5:488, 1984.

16. Wu, C.H., Plasma Free and Protein-Bound Testosterone in Hirsutism. Obstet. Gynecol. 60:188, 1982.













17. Bamman B.L., et al., Total and Free Testosterone During Pregnancy. Am. J. Obsetet. Gynecol. 137:293, 1980.

18. Halpern, E.P., et al., Production of Anti-Testosterone Antisera in Rabbits. Clin. Chem. 26:68, 1980.

19. Wheeler, M.J., The Determination of Bio-Available Testosterone. Ann. Clin. Biochem. 32:345, 1995.


20. Check, J.H., et al., Falsely Elevated Steroidal Assay Levels Related to Heterophile Antibodies Against Various Animal Species. Gynecol. Obstet. Invest. 40:139-140, 1995.

SYMBOLS

Symbol	Meaning	Symbol	Meaning
	In vitro diagnostic medical device		Storage temperature limit
	Manufacturer		Authorized representative in the European Community /European Union
	Date of Manufacture		Use-by date
	Do not re-use		Consult instructions for use or consult electronic instructions for use
	Batch code		Do not use if package is damaged and consult instructions for use
	Catalogue number		Contains sufficient for <n> tests



Hangzhou Realy Tech Co., Ltd.
#2 Building, No. 763, Yuansha Village, Xinjie Street, Xiaoshan District, 311200 Hangzhou City, Zhejiang Province, PEOPLE'S REPUBLIC OF CHINA
Website: www.realytech.com



Luxus Lebenswelt GmbH
Kochstr.1,47877, Willich, Germany

Number:1100052303
Version:1.6
Effective Date:2023-08-10